hrp0089fc13.4 | Pituitary, Neuroendocrinology and Puberty 2 | ESPE2018

The Kallman Syndrome Gene Product is Specifically Expressed in ACTH-Expressing Cells and Dysplays Sexual Dimorphism Expression in Human Fetal Pituitary

Guimiot Fabien , Bonnard Adeline , Soussi-Yaniscostas Nadia , Schnoll Carol , de Roux Nicolas

Kallman syndrome is defined by the association of anosmia due to an agenesis of the olfactory bulbs and hypogonadotropic hypogonadism due to a GnRH deficiency which is currently explained by a deficit of GnRH neuron migration from the olfactory placode toward the hypothalamus. In fact, the X-linked form of KS is due to loss of function mutations in ANOS1 which encodes an extracellular protein (ANOSMIN) interacting with cell membrane heparin sulfate proteoglycans but a...

hrp0095p1-34 | Diabetes and Insulin | ESPE2022

Early treatment of neonatal diabetes with oral glibenclamide suspension (Amglidia®) in an extremely preterm infant: evidence for efficacy, safety and easiness.

Galderisi Alfonso , Kermorvant-Duchemin Elsa , Daruich Alejandra , Alice Bonnard Adeline , Lapillonne Alexandre , Aubelle Marie-Stéphanie , Perrella Bruna , Cave Héléne , Berdugo Marianne , Jarreau Pierre-Henri , Polak Michel , Beltrand Jacques

Background: Early treatment of neonatal diabetes with sulfonylureas has shown to improve neurodevelopment, beyond the demonstrated efficacy on glycemic control. Several barriers still prevent its use as an early treatment in preterm babies including the limited availability of a suitable galenic form of glibenclamide. Recently, an oral suspension of glibenclamide (Amglidia®) has been approved for use in EU.Methods: W...